CARMAT, the designer and developer of artificial heart, has completed the assembly of the first clinical version of its artificial heart.

The artificial heart is expected to be implanted in humans during clinical trials scheduled for 2011.

The devices were assembled in CARMAT’s cleanroom facilities (inaugurated in October 2009).

CARMAT CEO Marcello Conviti said that reaching this key milestone – production of the artificial hearts that will be used in the clinical studies scheduled for 2011 – confirms that they are following the roadmap announced at the time of their IPO.

“We have achieved these objectives within two years of incorporation and just one year after inaugurating our cleanroom. CARMAT is continuing to implement its strategy for delivering the world’s most advanced artificial heart,” Conviti said.

France-based CARMAT is a Young Innovating Enterprise Biomedical financed by TRUFFLE CAPITAL, EADS and Professor Carpentier with the support of OSEO.